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anBACKGROUND The use of drug-eluting stents (DES) in patients at high risk of bleeding or thrombosis has not been
prospectively studied; limited data are available in patients who have a low restenosis risk.
OBJECTIVES This study sought to compare a hydrophilic polymer-based, second-generation zotarolimus-eluting stent
(ZES) with a unique drug fast-release proﬁle versus bare-metal stents (BMS) under similar durations of dual-antiplatelet
therapy (DAPT).
METHODS We randomly assigned 1,606 patients with stable or unstable symptoms, and who on the basis of thrombotic
bleeding or restenosis risk criteria, qualiﬁed as uncertain candidates for DES, to receive ZES or BMS. DAPT duration was
on the basis of patient characteristics, rather than stent characteristics, and allowed for a personalized 1-month dual
antiplatelet regimen. The primary endpoint was the risk of 1-year major adverse cardiovascular events (MACE), which
included death, myocardial infarction (MI), or target vessel revascularization (TVR).
RESULTS Median DAPT duration was 32 days (interquartile range [IQR]: 30 to 180 days) and did not differ between the
groups. In the ZES group, 140 patients (17.5%) reached the primary endpoint, compared with 178 patients (22.1%) in the
BMS group (hazard ratio: 0.76; 95% conﬁdence interval: 0.61 to 0.95; p ¼ 0.011) as a result of lower MI (2.9% vs. 8.1%;
p < 0.001) and TVR rates (5.9% vs.10.7%; p ¼ 0.001) in the ZES group. Deﬁnite or probable stent thrombosis was also
signiﬁcantly reduced in ZES recipients (2.0% vs. 4.1%; p ¼ 0.019).
CONCLUSIONS Compared with BMS, DES implantation using a stent with a biocompatible polymer and fast drug-
eluting characteristics, combined with an abbreviated, tailored DAPT regimen, resulted in a lower risk of 1-year MACE in
uncertain candidates for DES implantation. (Zotarolimus-eluting Endeavor Sprint Stent in Uncertain DES Candidates
[ZEUS] Study; NCT01385319) (J Am Coll Cardiol 2015;65:805–15) © 2015 by the American College of Cardiology
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ZES = zotarolimus-eluting
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806C ompared with bare metal stents(BMS), drug-eluting stents (DES)have consistently been shown to
reduce restenosis rates, and consequently,
the risk of target vessel failure (1–4). How-
ever, due to a higher incidence of very late
stent thrombosis, ﬁrst-generation DES raised
safety concerns (5–7). Therefore, to restore
safety to a level comparable to that after
BMS implantation, a prolonged course of
dual-antiplatelet therapy (DAPT) has been
recommended after DES implantation (8,9).SEE PAGE 816Consequently, the use of DES instead
of BMS remains controversial in selectedpatient and/or lesion subsets, including patients at
high thrombosis risk, who may have a higher risk for
coronary events after DES implantation, and those at
high bleeding risk, in whom long-term DAPT poses
safety concerns (9,10). Similarly, patients at a low
perceived risk for in-stent restenosis may not qualify
as good DES candidates, because the need for pro-
longed DAPT and the long-term risk for adverse
events after DES implantation may outweigh the
acknowledged beneﬁt of lower reintervention rates.
The zotarolimus-eluting stent (ZES) is a hydrophilic
polymer-based, second-generation device with a
uniquely fast drug-release proﬁle (11). The phosphor-
ylcholine coating has been shown to reduce thrombus
formation on the coated stent struts compared with
BMS (12). Although the rapid-release proﬁle may
result in less powerful inhibition of intimal hyper-
plasia, it may also lead to a more rapid and/or com-
plete stent strut coverage compared with other DES
(4,13,14), raising the possibility that it might be
feasible to shorten DAPT duration while maintaining
superior efﬁcacy compared with BMS (15). This could
be evaluated further in dedicated studies.
The purpose of this trial was to assess if ZES
implantation, followed by a shorter than the currently
recommended course of DAPT, on the basis of
the patient’s clinical proﬁle (tailored DAPT) andonic; honoraria for advisory board and lectures from The Medici
Abbott Vascular; and fees for lectures from Cordis, CID, and Te
rdiological Society and the Hellenic Institution of Cardiology. Dr
onic for Clinical Event Committee adjudications. Dr. Colangelo
l research grants from Abbott Vascular, Medtronic, Boston Scienti
honoraria from Abbott Vascular and Eli Lilly. All other authors ha
ents of this paper to disclose.
is manuscript’s audio summary by JACC Editor-in-Chief Dr. Vale
o listen to this issue’s audio summary by JACC Editor-in-Chief D
received June 23, 2014; revised manuscript received Novemberindependent of stent type, would decrease the inci-
dence of 12-month major adverse cardiovascular
events (MACE) in uncertain DES recipients, including
those with high bleeding or thrombotic risk and those
with low restenosis risk, compared with BMS.
METHODS
STUDY DESIGN AND POPULATION. The ZEUS
(Zotarolimus-eluting Endeavor sprint stent in Uncer-
tain DES candidates) trial is a multinational, ran-
domized, single-blinded trial, conducted at 20 sites in
4 European countries (Italy, Switzerland, Portugal,
and Hungary). It was designed to evaluate the com-
bined efﬁcacy and safety of ZES compared with BMS,
in uncertain DES candidates (16). Detailed inclusion
and exclusion criteria have been previously described
(16) and are detailed in the Online Appendix. In brief,
patients who underwent elective, urgent, or emer-
gent percutaneous coronary intervention with inten-
ded stent implantation were randomly assigned in a
1:1 fashion to ZES or a thin-strut (thickness <100 mm)
BMS, if they were ages 18 years or older and had at
least 1 qualifying criterion among the pre-speciﬁed
uncertain DES recipients. High-bleeding risk status
was deﬁned as the following: a clinical indication for
treatment with oral anticoagulant agents; recent
bleeding episode(s) that required medical attention;
previous bleeding episode(s) that required hospitali-
zation if the bleeding diathesis has not been
completely resolved (that is, surgical removal of
the bleeding source); age older than 80 years; sys-
temic conditions associated with increased bleeding
risk (e.g., hematological disorders or any known
coagulopathy-determining bleeding diathesis, in-
cluding history of or current thrombocytopenia,
which was deﬁned as platelet count <100,000/mm3
[<100  109/l]; known anemia, deﬁned as repeatedly
documented hemoglobin <10 g/dl; and need for long-
term treatment with steroids or nonsteroidal anti-
inﬂammatory drugs. High-risk thrombotic criteria
were deﬁned as the following: allergy and/or intol-
erance to aspirin; allergy and/or intolerance to avail-
able P2Y12 inhibitors; planned surgery (other thannes Company, Eli Lilly Co., Daiichi Sankyo, Inc., St.
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807skin) within 12 months of percutaneous coronary
intervention; patient with cancer (other than skin)
and life expectancy >1 year; and patients with sys-
temic conditions associated with thrombosis diath-
esis (e.g., hematological disorders and any known
systemic conditions determining a prothrombotic
state, including immunological disorders). Finally,
low restenosis risk was fulﬁlled if no planned
stent <3.0-mm diameter was intended to be implan-
ted, regardless of lesion length, apart from left main
coronary artery or saphenous graft intervention (17).
The ethics committees of all participating centers
independently approved the protocol, and all partic-
ipants gave written informed consent.
DEVICES. The Endeavor stent (Medtronic Vascular,
Minneapolis, Minnesota) is a cobalt-based alloy stent
(91-mm strut thickness) with a phosphorylcholine
polymer (4.8 mm) loaded with zotarolimus at a dose
concentration of 10 mg/mm stent length. Approxi-
mately 95% of the zotarolimus is eluted from the stent
within 15 days of implantation, although drug con-
centrations within surrounding vascular tissue may be
detected as late as 30 days after stent deployment.
Although all commercially available thin-strut
BMS (strut thickness <100 mm) were allowed to be
used in the study, the Tsunami, (Terumo, Leuven,
Belgium), Skylor (Medtronic, Minneapolis, Minne-
apolis), Integrity (Medtronic), Vision (Abbott, Santa
Clara, California), and Avant-Garde (CID Vascular,
Saluggia, Italy) were the 5 most commonly utilized
devices in this stent group.
TREATMENT PROTOCOL AND FOLLOW-UP PROCEDURES.
All eligible patients received aspirin (160 to 325 mg
orally or 500 mg intravenously as a loading dose
and then 80 to 160 mg orally per day) and clopidogrel
(300 or 600 mg orally as a loading dose followed by
75 mg/day), or prasugrel (60 mg loading dose fol-
lowed by 10 or 5 mg/day) or ticagrelor (180 mg loading
dose followed by 90 mg twice daily). Patients who
were not eligible for DAPT were treated with either
aspirin or clopidogrel (or prasugrel or ticagrelor)
monotherapy.
Duration of antiplatelet therapy was pre-speciﬁed
on the basis of the inclusion criteria. Patients at
high risk of bleeding had a pre-speciﬁed 30-day
DAPT regimen. Patients at high risk of thrombosis
had a pre-speciﬁed tailored duration of therapy on
the basis of the speciﬁc condition conferring the
high risk of thrombosis (Online Appendix). This
included a single antiplatelet regimen for patients
intolerant of aspirin or available P2Y12 inhibitors,
and a 30-day regimen in stable patients, or 6 to
12 months in unstable patients, in the group at low
risk of restenosis.Unfractionated heparin or bivalirudin was used for
anticoagulation during coronary intervention on the
basis of guideline-recommended regimens (8,9).
Staging was allowed by protocol; in patients allocated
to a 30-day course of DAPT who underwent staged
intervention(s), therapy had to be prolonged or
restarted for 30 additional days.
FOLLOW-UP. Protocol-mandated visits at 30 days,
6 months, and 12 months speciﬁcally assessed po-
tential intercurrent adverse events and compliance
with medications; a 12-lead electrocardiogram was
recorded.
STUDY ENDPOINTS. The purpose of this trial was to
assess whether ZES implantation followed by a
shorter than the currently recommended course of
DAPT, tailored to the patient’s clinical proﬁle
(tailored DAPT) and independent of stent type,
would decrease the incidence of 12-month MACE,
including all-cause death, nonfatal myocardial
infarction (MI), or any target vessel revascularization
(TVR), in uncertain candidates for DES trans-
plantation, including those at high bleeding or high
thrombotic risk and those at low restenosis risk (16)
compared with BMS.
Secondary endpoints included each component of
the primary endpoint: cardiac death; Academic
Research Consortium–deﬁned stent thrombosis (18);
all-cause or ischemic stroke; target lesion revascu-
larization; and bleeding. All potential event triggers
were assessed using source documents obtained from
the site and centrally adjudicated by the clinical
events committee, whose members were unaware of
treatment assignment. Detailed deﬁnitions of all
study endpoints are provided in the Online Appendix.
STATISTICAL ANALYSIS. Assuming an event rate of
15.0% at 1 year for the primary endpoint in patients
assigned to BMS (16), we estimated that at least 1,556
patients would need to be enrolled to detect a 33%
reduction in the relative risk of the primary endpoint
in the ZES group compared with the BMS group, with
a statistical power of 85% at a 2-sided signiﬁcance
level of 0.05. The ﬁnal sample size was increased to
1,600 patients (16).
Categorical variables were expressed as frequen-
cies (percents), whereas continuous variables were
expressed as medians (interquartile ranges [IQRs]).
Continuous variables were compared between ran-
domized groups using the Wilcoxon rank-sum test,
whereas the Fisher exact test was used for binary
variables. Further details of statistical analysis are
provided in the Online Appendix. A 2-sided
p value <0.05 was considered signiﬁcant. All ana-
lyses were performed on an intention-to-treat basis
TABLE 1 Baseline Characteristics of Patients*
BMS Group
(n ¼ 804)
ZES Group
(n ¼ 802)
Age, yrs 71.8  12 71.8  11
Median 73.6 73.9
Interquartile range 64.0–81.0 63.8–81.0
Range 31.3–100.2 31.6–94.8
Female 232 (28.9) 241 (30.0)
Body mass index, kg/m2
Median 26.5 26.7
Interquartile range 24.2–29.3 24.2–29.4
Diabetes 205 (25.5) 215 (26.8)
Hypertension 605 (75.2) 612 (76.3)
Hyperlipidemia 399 (49.6) 381 (47.5)
Current cigarette use 169 (21.0) 167 (20.8)
Creatinine clearance, ml/min†
Median 66.0 66.0
Interquartile range 47.9–88.6 46.1–90.8
Patients with creatinine clearance <60 ml/min† 327 (41.7) 317 (41.2)
Patients with creatinine clearance <30 ml/min† 66 (8.4) 64 (8.3)
Patients on dialysis 12 (1.5) 21 (2.6)
Previous MI 190 (23.6) 194 (24.2)
Previous percutaneous coronary intervention 149 (18.5) 155 (19.3)
Previous coronary bypass surgery 59 (7.3) 54 (6.7)
Previous stroke or transient ischemic attack 53 (6.6) 51 (6.4)
Chronic obstructive pulmonary disease 65 (8.1) 55 (6.9)
Peripheral arterial disease 141 (17.5) 117 (14.6)
Left ventricular ejection fraction‡
Median 50.0 50.0
Interquartile range 40–55 40–56
Clinical presentation
Stable angina pectoris 295 (36.7) 295 (36.8)
Acute coronary syndrome 509 (63.3) 507 (63.2)
Unstable angina 131 (16.3) 139 (17.3)
Non–ST-segment elevation MI 226 (28.1) 215 (26.8)
ST-segment elevation MI 152 (18.9) 153 (19.1)
Angiographic features
Single-vessel disease 313 (38.9) 332 (41.4)
Double-vessel disease 285 (35.4) 266 (33.2)
Triple-vessel disease 206 (25.6) 204 (25.4)
Inclusion criteria
High bleeding risk 404 (50.2) 424 (52.9)
High thrombosis risk 145 (18.0) 140 (17.5)
Low restenosis risk
Stable coronary artery disease presentation 167 (20.8) 170 (21.2)
Unstable coronary artery disease presentation 301 (37.4) 303 (37.8)
Values are mean  SD or n (%), unless otherwise indicated. *There were no signiﬁcant between-
group differences. †Available in 784 patients (97.5%) in the BMS group and 769 patients (95.9%)
in the ZES group. ‡Available in 748 patients (93%) in the BMS group and 742 patients (93%) in
the ZES group.
BMS ¼ bare-metal stent(s); MI ¼ myocardial infarction; ZES ¼ zotarolimus-eluting stent(s).
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808using STATA version 11.1 (Stata Corp., College Station,
Texas).
RESULTS
From June 2011 to September 2012, 5,288 patients
were screened and 1,606 were ﬁnally randomized(Online Figure 1). The groups were well balanced with
regard to baseline clinical and angiographic charac-
teristics (Tables 1 and 2).
The median age was 74 years; approximately one-
quarter of the patient population had a history of
diabetes or previous MI, and >40% of patients had
impaired kidney function. Nearly two-thirds of
patients presented with acute coronary syndromes
(acute ST-segment elevation MI in 20%), and more
than one-half had multivessel disease. One-third
of patients received treatment for >1 lesion, and
approximately 1 patient in every 4 underwent mul-
tivessel intervention. At least 1 complex lesion
was treated in approximately 75% of the patients
(Table 2).
CHARACTERIZATION OF THE INCLUDED PATIENT
POPULATION. Figure 1A shows the distribution of the
inclusion criteria in the recruited patient population.
Approximately one-half of the patients (n ¼ 828)
entered the study due to high bleeding risk criteria,
dictated by age 80 years or older in 425 (26.5%) pa-
tients and/or need for oral anticoagulation in 311
(19.4%) patients. Other high bleeding risk criteria
included the following: ongoing, recent (within
12 months), or previous bleeding events requiring
medical attention or hospitalization in 116 (7.2%)
patients; presence of comorbidities determining an
increased bleeding risk in 54 (3.4%) patients; known
anemia in 68 (4.2%) patients; and need for pro-
longed treatment with steroids or nonsteroidal anti-
inﬂammatory drugs in 25 (1.6%) patients. A high
thrombotic risk was detected in 285 (17.7%) patients
on the basis of the following: planned cardiac or
noncardiac surgery in 117 (7.3%) patients; intolerance
to aspirin (n ¼ 73) or any P2Y12 inhibitor (n ¼ 1) in
74 (4.6%) patients; and cancer in 84 (5.2%) patients.
DUAL ANTIPLATELET THERAPY. DAPT was used in
1,532 (95.4%) patients, aspirin and clopidogrel in
1,481 patients (96.7%), and aspirin and prasugrel
(n ¼ 49) or ticagrelor (n ¼ 2) in the remaining 51 (3.3%)
patients. Figure 1B shows the cumulative frequency of
DAPT duration from randomization to the ﬁrst plan-
ned permanent discontinuation in the 2 study groups.
The median duration of DAPT, 32 days (IQR: 30 to 180
days), did not differ between groups (33 days [IQR: 30
to 180 days] for BMS vs. 31 days [IQR: 30 to 180 days]
for ZES groups; p ¼ 0.69). Overall, 1,077 (67%) pa-
tients (533 [66.3%] in the BMS group and 544 [67.8%]
in the ZES group) qualiﬁed for a 1-month DAPT
regimen or a single antiplatelet regimen on the basis
of inclusion criteria; the median duration of DAPT in
these patients was 31 days (IQR: 30 to 81 days) in
the BMS group versus 30 days (IQR: 30 to 48 days)
(p ¼ 0.89) in the ZES group. Reasons for prolonging
TABLE 2 Procedural Results and Use of Medications
During the Trial*
BMS
(n ¼ 804)
ZES
(n ¼ 802)
No. of treated lesions 1,153 1,172
Mean  SD 1.43  0.72 1.46  0.75
Median 1 1
Interquartile range 1–2 1–2
Range 1–6 1–6
$2 treated lesions 272 (33.8) 276 (34.4)
Multivessel intervention 229 (25.6) 246 (27.8)
LAD treated 411 (51.1) 421 (52.5)
CFX treated 278 (34.6) 263 (32.8)
RCA treated 317 (39.4) 335 (41.8)
LMCA treated 36 (4.5) 39 (4.9)
SVG treated 12 (1.5) 9 (1.1)
At least 1 complex (type B2 or C)
lesion†
590 (73.4) 585 (72.9)
Total ACC/AHA score†‡
Mean  SD 6.82  4.2 6.67  4.2
Median 6 6
Interquartile range 4–10 3–9
Number of stents implanted
Mean  SD 1.69  1.10 1.70  1.11
Median 1 2
Interquartile range 1–2 1–2
Range 0–9 0–7
Length of stent, mm
Median 26 30
Interquartile range 18–45 18–47
Range 0–176 0–144
Mean stent diameter, mm
Median 3 3
Interquartile range 2.80–3.50 2.83–3.50
Patients receiving $2 stents 199 (24.8) 201 (25.1)
Patients receiving $3 stents 71 (8.8) 93 (11.6)
Patients with overlapping stents 187 (23.3) 193 (24.1)
Continued in the next column
TABLE 2 Continued
BMS
(n ¼ 804)
ZES
(n ¼ 802)
Quantitative coronary analysis
Lesion length, mm 16.30  10.48 16.58  10.74
Reference vessel diameter,
before, mm
2.85  0.88 2.86  0.76
Minimal lumen diameter,
before, mm
1.07  0.56 1.08  0.54
Stenosis, before, % 67  16 68  16
Reference vessel diameter,
after, mm
2.90  0.50 2.95  0.51
Minimal lumen diameter,
after, mm
2.70  0.50 2.73  0.52
Stenosis, after, % 6.9  7.3 7.01  7.39
Drug therapy at discharge
Aspirin 745 (92.7) 743 (92.6)
P2Y12 inhibitor 781 (97.1) 784 (97.8)
ACE inhibitors 517 (64.3) 514 (64.1)
Beta-blockers 604 (75.1) 588 (73.3)
Statins 695 (86.4) 684 (85.3)
Oral anticoagulant agent 101 (12.6) 107 (13.3)
Proton pump inhibitors 522 (65.1) 520 (65.1)
Drug therapy at 30 days
Aspirin 739 (91.9) 732 (91.3)
P2Y12 inhibitor 753 (93.7) 753 (93.9)
ACE inhibitors 489 (60.8) 506 (63.1)
Beta-blockers 587 (73.0) 590 (73.6)
Statins 670 (83.3) 663 (83.9)
Oral anticoagulant agent 108 (13.4) 105 (13.1)
Proton pump inhibitors 506 (62.9) 506 (63.1)
Values are mean  SD or n (%), unless otherwise indicated. *There were no
signiﬁcant between-group differences. †Calculated in 802 patients in the BMS arm
and in 800 patients in the ZES arm; ACC/AHA scores were missing in 6 patients.
‡As described in Ellis et al. (30), type A stenoses were coded 1 point; type B1
stenoses, 2 points; type B2 stenoses, 3 points; and type C stenoses, 4 points.
ACC/AHA ¼ American College of Cardiology/American Heart Association;
ACE ¼ angiotensin-converting enzyme; CFX ¼ circumﬂex artery; LAD ¼ left
anterior descending artery; LMCA ¼ left main coronary artery; RCA ¼ right coro-
nary artery; SVG ¼ saphenous vein graft; other abbreviations as in Table 1.
J A C C V O L . 6 5 , N O . 8 , 2 0 1 5 Valgimigli et al.
M A R C H 3 , 2 0 1 5 : 8 0 5 – 1 5 Zotarolimus Stent in Uncertain DES Candidates
809DAPT beyond 30 days in this patient population
included planned staged procedures or new coronary
lesions that required intervention.
There were 74 (4.6%) patients with aspirin or P2Y12
inhibitor intolerance who did not receive DAPT; 499
(62.1%) patients in the BMS group and 505 (63.0%)
patients in the ZES group received DAPT for <2
months (p ¼ 0.72). DAPT was restarted during follow-
up in 42 (5.2%) patients in the BMS group and in 27
(3.4%, p ¼ 0.084) patients in the ZES group, mostly
due to new coronary events and/or new unplanned
coronary intervention. As a result, the cumulative
DAPT duration trended slightly longer in the BMS
group (median [IQR]: 34 days [30 to 184 days] vs. 33
days [30 to 180 days] in the ZES group, p ¼ 0.063)
(Online Figure 2).
CLINICAL OUTCOMES. During follow-up, 140 pa-
tients (17.5%) in the ZES group and 178 patients (22.1%)in the BMS arm reached the primary endpoint (hazard
ratio [HR]: 0.76; 95% conﬁdence interval [CI]: 0.61 to
0.95; p ¼ 0.011), supporting the primary hypothesis of
superior efﬁcacy (Central Illustration A, Table 3). The
difference between groups reﬂected a signiﬁcant
reduction in MI (2.9% in the ZES group vs. 8.1% in the
BMS group; HR: 0.35; 95% CI: 0.22 to 0.56; p < 0.001)
(Central Illustration B) and a signiﬁcant decrease in TVR
in the ZES group (5.9% in the ZES group vs. 10.7% in the
BMS group; HR: 0.53; 95% CI: 0.37 to 0.75; p ¼ 0.001)
(Central Illustration C, Table 3). Although all-cause and
cardiovascular mortality did not differ signiﬁcantly in
the ZES cohort (11.1% and 7.6%, respectively) and the
BMS cohort (11.4%; HR: 0.97; 95% CI: 0.72 to 1.29; p ¼
0.83 and 8.3%; HR: 0.91; 95% CI: 0.64 to 1.29; p ¼ 0.65,
respectively) (Table 3), the composite of any death or
nonfatal MI, as well as of cardiovascular death or
FIGURE 1 Characterization of the Study Population and Duration of Dual Antiplatelet Therapy
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(A) Venn diagram: the numbers reported outside each circle indicate the cumulative frequency of each recruiting condition, including high
bleeding risk (n ¼ 828 [51.6%]), high thrombotic risk (n ¼ 285 [17.7%]), low restenosis risk with unstable presentation (n ¼ 604 [37.6%]), and
low restenosis risk with stable presentation (n ¼ 337 [21%]), whereas the numbers reported in each circle of the Venn diagram indicate the
frequency of each recruiting condition as a standalone feature, and the numbers in the overlap regions reﬂect the frequency with which each
recruiting condition overlap with others. (B) The cumulative frequency curve for the duration of DAPT in each stent group during follow-up.
Duration of DAPT was quantiﬁed in days of therapy from randomization to ﬁrst planned permanent discontinuation (when either of the drugs
was stopped on the basis of protocol recommendations or by the treating physician, with no intention to restart treatment at a later date).
BMS ¼ bare-metal stent(s); DAPT ¼ dual antiplatelet therapy; ZES ¼ zotarolimus-eluting stent(s).
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810nonfatal MI were both signiﬁcantly reduced in the ZES
group (13.1% vs. 17.4%; HR: 0.73; 95% CI: 0.57 to 0.94;
p¼ 0.018 and 9.7% vs. 14.6%; HR: 0.65; 95% CI: 0.49 to
0.87; p ¼ 0.004, respectively).
The rate of deﬁnite stent thrombosis trended lower
in the ZES group (1.0% in the ZES group vs. 2.2%
in the BMS group; HR: 0.44; 95% CI: 0.19 to 1.02;
p ¼ 0.054), whereas the composite of deﬁnite or
probable thrombosis (2.0% vs. 4.1%; HR: 0.48; 95%
CI: 0.27 to 0.88; p ¼ 0.019) (Central Illustration, D) and
deﬁnite, probable, or possible stent thrombosis (4.7%
vs. 7.2%; HR: 0.65; 95% CI: 0.43 to 0.97; p ¼ 0.045)
were both signiﬁcantly reduced in the ZES group.
Bleeding endpoints, reported in Table 3, did not differ
between groups.
SUBGROUP ANALYSIS. As shown in Figure 2, when
outcomes in terms of the primary endpoint of death
from any cause, MI, or TVR, as well as for the sec-
ondary endpoint of death from any cause or MI were
separately appraised across patients at high risk of
bleeding or thrombosis or at low risk of restenosis,
there was no signal of heterogeneity.
DISCUSSION
The ZEUS study focused on a unique patient popu-
lation that was largely excluded from the pivotalDES trials that led to regulatory approval. We stud-
ied patients with high bleeding risk, high thrombotic
risk, or low restenosis risk. Furthermore, the dura-
tion of antiplatelet therapy speciﬁed in the protocol
was based not on the type of stent implanted
(DES vs. BMS), but on the patient’s perceived risk
proﬁle.
The advent of DES led to the recommendation that
a more prolonged course of DAPT be mandated,
compared with the shorter duration recommended
for BMS (1,19). Hence, the effect of DES implantation
has never been disentangled from that offered by a
prolonged DAPT regimen.
The principal research question posed was whether
the use of ZES compared with BMS, both with similar
short courses of DAPT, would translate into a reduc-
tion of MACE at 1 year (Central Illustration). The pri-
mary hypothesis of superior efﬁcacy of the ZES was
conﬁrmed and driven by a lower TVR rate and a lower
rate of MI in the ZES group compared with the BMS
group. Our study results conﬁrmed the previously
demonstrated beneﬁt of lower TVR rates in more
selected populations by showing an almost 50%
relative and 5% absolute reduction of this endpoint in
the ZES group compared with the BMS group. We also
observed an unexpected reduction in the overall rates
of MI and stent thrombosis that favored the use of
CENTRAL ILLUSTRATION Zotarolimus-Eluting Stent in Uncertain Drug-Eluting Stent Candidates: Kaplan-Meier Curves
of Study Outcomes
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(A) Rates of events for the primary composite outcome (death, MI, or TVR) and the principal secondary outcomes, including (B)MI, (C) TVR, and (D) deﬁnite or probable
stent thrombosis at 1 year are shown. BMS ¼ bare-metal stent(s); MI ¼ myocardial infarction; TVR ¼ target vessel revascularization; ZES ¼ zotarolimus-eluting stent(s).
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811ZES. The risk of MI was reduced in the ZES group by
>60% on a relative basis and by 5% on an absolute
basis. At post hoc analysis, rate of type I (sponta-
neous) and type IVb (stent thrombosis-related) MI
were signiﬁcantly reduced in the ZES arm, whereas
other types of MI, including peri-procedural events,
did not differ between the 2 groups. The composite ofdeﬁnite or probable stent thrombosis was reduced by
>50% in the ZES group, with an absolute difference
in event rates of 2.1%. At sensitivity analysis, the
beneﬁt in terms of the study primary endpoint
appeared consistent throughout the subgroups,
including in those who (as per protocol) received an
abbreviated 30-day DAPT regimen or a single
TABLE 3 Outcome Rates at 12 Months According to Treatment Group
BMS
(n ¼ 804)
ZES
(n ¼ 802)
Hazard Ratio
(95%CI) p Value
Primary efﬁcacy endpoint
Death from any cause, myocardial
infarction or target vessel
revascularization
178 (22.1) 140 (17.5) 0.76 (0.61–0.95) 0.011
Secondary efﬁcacy endpoints
Death from any cause or
myocardial infarction
140 (17.4) 105 (13.1) 0.73 (0.57–0.94) 0.018
Death from cardiovascular cause
or myocardial infarction
117 (14.6) 78 (9.7) 0.65 (0.49–0.87) 0.004
Death from any cause 92 (11.4) 89 (11.1) 0.97 (0.72–1.29) 0.83
Death from cardiovascular cause 67 (8.3) 61 (7.6) 0.91 (0.64–1.29) 0.65
Myocardial infarction 65 (8.1) 23 (2.9) 0.35 (0.22–0.56) <0.001
Target vessel revascularization 86 (10.7) 47 (5.9) 0.53 (0.37–0.75) 0.001
Target lesion revascularization 84 (10.4) 42 (5.2) 0.48 (0.33–0.70) <0.001
Ischemic stroke 12 (1.5) 9 (1.1) 0.75 (1.32–1.77) 0.71
Deﬁnite stent thrombosis* 18 (2.2) 8 (1.0) 0.44 (0.19–1.02) 0.054
Probable stent thrombosis* 15 (1.9) 8 (1.0) 0.53 (0.23–1.25) 0.21
Possible stent thrombosis* 25 (3.1) 22 (2.7) 0.86 (0.49–1.53) 0.60
Deﬁnite or probable stent thrombosis* 33 (4.1) 16 (2.0) 0.48 (0.27–0.88) 0.019
Deﬁnite, probable, or possible stent
thrombosis*
58 (7.2) 38 (4.7) 0.65 (0.43–0.97) 0.045
Safety endpoints
TIMI classiﬁcation 17 (2.1) 14 (1.7) 0.72
Major or minor
Major 13 (1.6) 7 (0.9) 0.26
Minor 4 (0.5) 7 (0.9) 0.39
Requiring medical attention 35 (4.4) 28 (3.5) 0.44
BARC classiﬁcation†
Type 5 or 3 25 (3.1) 22 (2.7) 0.77
Type 5, 3 or 2 53 (6.6) 41 (5.1) 0.24
Type 5 7 (0.9) 4 (0.5) 0.55
Type 5A 4 (0.5) 3 (0.4) >0.99
Type 5B 3 (0.4) 1 (0.1) 0.63
Type 4 0 0 .
Type 3 18 (2.2) 18 (2.2) >0.99
Type 3A 6 (0.7) 5 (0.6) >0.99
Type 3B 10 (1.2) 12 (1.5) 0.68
Type 3C 2 (0.2) 1 (0.1) >0.99
Type 2 28 (3.5) 19 (2.4) 0.24
Values are n (%), unless indicated otherwise. *Stent thrombosis was deﬁned according to Academic Research
Consortium criteria. †Type 5 refers to fatal bleeding; Type 4 are coronary artery bypass-related bleedings; Type 3
bleedings are divided into: 3A, overt bleeding plus hemoglobin drop of 3 to <5 g/dL or any transfusion with overt
bleeding; 3B, overt bleeding plus hemoglobin drop $5 g/dl or cardiac tamponade or bleeding requiring surgical
intervention for control (excluding dental/nasal/skin/hemorrhoid) or bleeding requiring intravenous inotropes;
and 3C, intracranial hemorrhage or intraocular bleed compromising vision. Type 2 bleedings are any overt,
actionable sign of hemorrhage that does not ﬁt the criteria for Types 3, 4, or 5, but does meet at least 1 of the
following criteria: 1) requiring nonsurgical medical intervention by a health care professional; 2) leading to
hospitalization or increased level of care; or 3) prompting evaluation.
BARC ¼ Bleeding Academic Research Consortium; TIMI ¼ Thrombolysis In Myocardial Infarction; other
abbreviations as in Table 1.
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812antiplatelet agent. Hence, our results suggest, for the
ﬁrst time, that ZES implantation followed by a
personalized duration of DAPT, including a 30-day
course of DAPT, is a novel and attractive strategy to
reduce rates of MACE without increasing the risk of
bleeding. The cumulative duration of DAPT trendedlonger in the BMS group, driven by the higher num-
ber of patients in this group who experienced a new
MI and/or reintervention in the target vessel during
follow-up. Although bleeding events did not differ
between the 2 study groups at 1 year, further follow-
up is needed to ascertain the long-term clinical im-
plications of these ﬁndings, speciﬁcally the effect on
cumulative bleeding endpoints of long-term DAPT
duration in the BMS group and in the subgroup of
patients (numerically almost 2-fold more than in the
ZES group) who required reintervention for in-stent
restenosis.
Observational registry (15,20) data and 3 inde-
pendent randomized controlled trials (21–24) have
provided reassurance on the safety of reducing
DAPT duration to 6 months, or even 3 months, after
ZES implantation. Moreover, long-term results of
the PROTECT (Randomized Study Comparing En-
deavor With Cypher Stents) study suggested that
adherence to DAPT modiﬁes the outcome of stent
thrombosis to a greater extent after sirolimus-
eluting stent deployment than after ZES deploy-
ment, which is most likely due to differential
healing characteristics (25). These ﬁndings reinforce
the concept that DAPT use should be taken into
consideration when interpreting the incidence of
stent thrombosis and ischemic outcomes in studies
that evaluate different stent platforms (25). The
results of the ZEUS study further extend these
ﬁndings by demonstrating that a very short (30-day)
course of therapy in the ZES group did not pose a
signiﬁcant risk, whereas it achieved superior clinical
efﬁcacy.
The ZES is a unique second-generation device, in
that it is completely hydrophilic polymer-based, and
has a speciﬁc fast-release drug proﬁle. Although the
rapid-release proﬁle (<2 weeks) results in less
powerful inhibition of intimal hyperplasia (4), it leads
to more rapid and complete stent strut coverage
compared with other DES, suggesting that it might be
feasible to shorten DAPT duration while maintaining
superior efﬁcacy compared with BMS (11,15,26).
The thrombogenicity of BMS has long been recog-
nized (27).
The polymer coating in the ZES is hydrophilic and
highly biocompatible, and potentially serves as a
barrier to diminish the thrombogenic potential of the
metal stent struts (11). Multiple studies comparing
new-generation DES versus BMS have observed a
lower stent thrombosis and/or target vessel–related
MI risk after DES (5,28,29). The interplay between
the lower thrombogenicity of the device and the
ability to reduce late loss–related coronary events
has been formulated as a putative explanation for
FIGURE 2 Subgroup Analyses
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Subgroup analyses for the 3 major inclusion criteria for which randomization was stratiﬁed are shown, with HRs and 95% CIs for the primary
endpoint of death from any cause, MI, or TVR, as well as for the secondary endpoint of death for any cause or MI in 1,606 patients randomly
assigned to either ZES or BMS. The p value for interaction represents the likelihood of interaction between the variable and the relative
treatment effect. CI ¼ conﬁdence interval; HR ¼ hazard ratio; MI ¼ myocardial infarction; TVR ¼ target vessel revascularization; other
abbreviations as in Figure 1.
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813these ﬁndings. However, all these studies have sys-
tematically mandated a prolonged (and frequently
much longer) DAPT regimen for DES patients
compared with BMS patients (4,28,29). Hence, these
studies (unlike ours) failed to disentangle the effects
of the device from those of the concomitant anti-
platelet therapy.
STUDY LIMITATIONS. Our study had several limita-
tions. It was not powered to assess the effect of ZES
implantation with tailored duration of DAPT on
purely stent-driven endpoints, such as deﬁnite or
probable stent thrombosis. Nevertheless, our obser-
vation of a lower risk of stent thrombosis in the ZES
arm was reassuring. This study had a single-blind
design, and no speciﬁc safeguards were adopted to
ensure that patients and treating physiciansremained unaware of treatment allocation beyond
formal recommendations in the protocol. Thus, our
study should be regarded as an open-label study with
evident limitations.
Because of the unique properties of the ZES, our
results should not be extrapolated to newer gene-
ration DES coated with the same or other anti-
proliferative agents and diverse polymers.
Because the ZES has been associated with a lower
efﬁcacy in preventing TVR compared with other more
potent ﬁrst- or second-generation DES (4), it remains
unclear if other DES may offer similar advantages,
especially in patients at high risk of bleeding or
thrombosis.
Further research is needed to ascertain if the
tailored DAPT regimen tested in our study can be
safely implemented in patients who receive other
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Pa-
tients with contraindications to DES exhibited better
outcomes when treated with ZES followed by a rela-
tively short course of DAPT compared with BMS, as
assessed in terms of survival and freedom from MI or
TVR.
TRANSLATIONAL OUTLOOK: Further studies are
needed to determine whether other types of DES
offer similar advantages over BMS when DAPT is
adjusted according to individual patient characteris-
tics rather than stent type.
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814DES. Longer follow-up is needed to assess the dura-
bility of our study results over time.
CONCLUSIONS
The ZEUS study showed that a treatment strategy
consisting of ZES implantation followed by a per-
sonalized course of DAPT, including a 30-day course
of therapy, resulted in a lower risk of MACE compared
with BMS in patients at high risk of bleeding or
thrombosis or at low risk of restenosis.
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